Hemoporfin-mediated photodynamic therapy for the treatment of port-wine stain: A multicenter, retrospective study
Xiaofeng Zhang, Chen Yuan, Xuemin Xiao, Rui Yin, Hongzhao Lei, Yan Li, Shumao Zheng, Sijian Wen, Dongsheng Li, Xuejun Wang, Lu Zhong, Yunfeng Zhang, Weihui Zeng, Sijin He, Yuzhen Li, Dan Jian, Jun Yang, Hua Zhong, Dawei Han, Xiaoying Chen, Junfeng Zhou, Yantao Cai, Xi Peng, Zhiming Li, Xueying Liu, Tong Lin, Ruzhi Zhang, Guang Li, Yin Zhuang, Ling Liu, Yan Yan, Baoxi Wang
Abstract
BACKGROUND: Hemoporfin-mediated photodynamic therapy (Hemoporfin-PDT) has been approved for port-wine stain (PWS) in China in 2017. This study evaluated the efficacy and safety of Hemoporfin-PDT for PWS in a real life setting and investigated factors that influence the efficacy. METHODS: A multicenter retrospective study included patients with PWS who underwent Hemoporfin-PDT in 29 hospitals across China and completed at least two months of follow-up. The efficacy was evaluated based on patien photographs. RESULTS: A total of 1679 patients were included. After the first and second sessions of Hemoporfin-PDT, 63.5 and 75.3% of patients responded, respectively. The response rate of purple-type PWS was significantly lower than that of pink-type PWS (OR: 0.71, 95% CI: 0.54-0.94, P < 0.05), and there was no significant difference between thick- and pink-type (OR: 0.72, 95% CI: 0.42-1.22, P > 0.05). The response rate of PWS on the limbs was significantly lower than that on the mid-face (OR: 0.35, 95% CI: 0.23-0.53, P < 0.0001), while no significant difference was observed between PWS on the peripheral part of the face, neck or other parts of the body and PWS on the mid-face (P > 0.05). The response rate was lower in male patients with an age > 3 years or ≤ 6 years (P < 0.05). Previous treatment history did not affect the efficacy (P > 0.05). Hemoporfin-PDT was well tolerated. CONCLUSION: Patients with PWS have a good response and good tolerance to Hemoporfin-PDT.